A Role of the ABCC4 Gene Polymorphism in Airway Inflammation of Asthmatics
Table 3
Association of ABCC4 −1508A>G polymorphism with clinical features, metabolite, and cytokine profiles in asthmatic patients.
Clinical features
AA ()
AG/GG ()
value
Age (years)†
39.01 ± 14.34
40.92 ± 15.09
0.735
Sex, male (%)‡
32.14
28.57
0.335
Atopy (%)‡
57.46
51.18
0.928
Total IgE (IU/mL)†
451.48 ± 965.78
278.32 ± 319.68
0.240
Rhinosinusitis (%)‡
81.21
18.78
0.143
Nasal polyp (%)‡
81.11
18.88
0.889
FEV1 (%)†
86.45 ± 19.66
87.54 ± 14.57
0.638
PC20 methacholine (mg/mL)
10.19 ± 17.07
5.82 ± 8.04
0.119
Total IgE
451.48 ± 965.78
278.32 ± 319.69
0.24
Asthma duration (years)†
6.30 ± 6.03
12.81 ± 32.36
0.237
Inflammatory cytokines
AA ()
AG/GG ()
value
MPO (μg/L)†
108.26 ± 79.5
150.91 ± 94.13
0.027
IL-8 (pg/mL)†
16.82 ± 14.45
14.47 ± 7.5
0.616
IL-18 (pg/mL)†
247.77 ± 166.06
281.92 ± 197.10
0.560
Eotaxin-1 (ng/mL)†
85.67 ± 63.67
85.22 ± 65.11
0.841
Eotaxin-2 (ng/mL)†
1146.92 ± 802.14
1104.95 ± 641.09
0.650
Periostin (ng/mL)†
71.07 ± 33.62
91.83 ± 50.85
0.016
Serum metabolites (ng/mL)
AA ()
AG/GG ()
value
15-HETE
265.98 ± 185.69
334.34 ± 132.47
0.195
LTE4
18.22 ± 17
18.8 ± 14.71
0.731
PGF2α
23.55 ± 9.3
21.96 ± 8.69
0.653
TXB2
0.41 ± 0.42
0.39 ± 0.17
0.952
Eoxin C4
4.82 ± 9.5
8.14 ± 11.95
0.224
S1P
111.75 ± 42.16
120.91 ± 42.88
0.419
Urinary metabolites (pmol/mg Cr)
AA ()
AG/GG ()
value
15- HETE
271.91 ± 89.87
332.5 ± 99.31
0.032
LTE4
7648.29 ± 14378.31
2601.73 ± 3043.59
0.616
PGF2α
8618.51 ± 22942.8
1678.71 ± 978.76
0.65
TXB2
5686.61 ± 4305.7
4798.25 ± 3957.21
0.765
Eoxin C4
144.78 ± 94.07
124.75 ± 46.65
0.602
S1P
32.56 ± 8.25
41.5 ± 9.35
0.010
†Values were presented as mean ± SD, whereas ‡ values were shown as percentage. Cr: creatinine; LTE4: leukotriene E4; PGF2α: prostaglandin F2α; TXB2: thromboxane B2; 15-HETE: 15-hydroxyeicosatetraenoic acid; MPO: myeloperoxidase; S1P: sphingosine-1-phosphate. value was obtained by logistic regression analysis with age and sex as covariates.
